CASI PHARMACEUTICALS INC(NASDAQ:CASI) stock News

CASI Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Benzinga - Mentions: SNGX SSKN CRNX APLT ...

12 Health Care Stocks Moving In Friday's Intraday Session

12 days ago - By: ACCESS Newswire

CASI Pharmaceuticals Appoints James Huang to Board of Directors

a month ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

a month ago - By: ACCESS Newswire

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: ACCESS Newswire

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

a month ago - By: Benzinga - Mentions: CGC FBIO AQB MODD ...

12 Health Care Stocks Moving In Friday's After-Market Session

2 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

a month ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

a month ago - By: ACCESS Newswire

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

a month ago - By: Zacks Investment Research - Mentions: VEEV

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: VYNE

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: VXRT

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: XBIO

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: CRNX

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

2 months ago - By: Zacks Investment Research - Mentions: BVS

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

3 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

5 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Provides Business and Clinical Update

5 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

5 months ago - By: Zacks Investment Research - Mentions: AQST

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

5 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

6 months ago - By: Stocktwits - Mentions: GM

CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

6 months ago - By: ACCESS Newswire

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

6 months ago - By: ACCESS Newswire

CASI PHARMACEUTICALS INC (CASI) Stock News

CASI Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Friday's Intraday Session

CASI Pharmaceuticals Appoints James Huang to Board of Directors

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors

12 Health Care Stocks Moving In Friday's After-Market Session

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

CASI Pharmaceuticals Provides Business and Clinical Update

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results